TY - JOUR
T1 - /targeted treatments for multiple myeloma
T2 - Specific role of carfilzomib
AU - Sugumar, Dhivya
AU - Keller, Jesse
AU - Vij, Ravi
N1 - Publisher Copyright:
© 2015 Sugumar et al.
PY - 2015/1/21
Y1 - 2015/1/21
N2 - Carfilzomib is a selective, irreversible proteasome inhibitor, initially approved in the US in 2012 as single-agent therapy for relapsed and refractory multiple myeloma. Numerous Phase II studies have evaluated carfilzomib in the relapsed and refractory as well as the newly diagnosed setting, and Phase III studies are entering their final analysis. Data continue to grow to support its use as both single-agent therapy and in combination with immunomodulatory and other novel agents. This review discusses the role of carfilzomib in the treatment of multiple myeloma. Its mechanism of action, pharmacokinetics, and role in clinical management will be reviewed.
AB - Carfilzomib is a selective, irreversible proteasome inhibitor, initially approved in the US in 2012 as single-agent therapy for relapsed and refractory multiple myeloma. Numerous Phase II studies have evaluated carfilzomib in the relapsed and refractory as well as the newly diagnosed setting, and Phase III studies are entering their final analysis. Data continue to grow to support its use as both single-agent therapy and in combination with immunomodulatory and other novel agents. This review discusses the role of carfilzomib in the treatment of multiple myeloma. Its mechanism of action, pharmacokinetics, and role in clinical management will be reviewed.
KW - Novel agents
KW - Proteasome inhibitor
KW - Relapsed and refractory
KW - Targeted therapy
UR - http://www.scopus.com/inward/record.url?scp=84930476178&partnerID=8YFLogxK
U2 - 10.2147/PGPM.S39085
DO - 10.2147/PGPM.S39085
M3 - Review article
C2 - 25691814
AN - SCOPUS:84930476178
SN - 1178-7066
VL - 8
SP - 23
EP - 33
JO - Pharmacogenomics and Personalized Medicine
JF - Pharmacogenomics and Personalized Medicine
ER -